Guildford, UK, and Burlington, Mass., July 14, 2011 - IDBS, a global provider of innovative data management, analytics and modeling solutions, today announced it is expanding its business in Burlington, Massachusetts, and establishing its U.S. Healthcare headquarters in that office.
At the recent 2011 BIO International Convention in Washington, D.C., Massachusetts Governor Deval Patrick, Dr. Susan Windham-Bannister, President and CEO of the Massachusetts Life Sciences Center, and representatives from MassBio and the Massachusetts International Trade Office met with Chris Molloy, VP of Business Development at IDBS, to discuss the importance of informatics in R&D and in the delivery of personalized medicine in the U.S., as well as opportunities for UK-Massachusetts collaboration and business development within the State. That meeting followed on the Governor’s recent Massachusetts Innovation Economy Partnership Mission to the UK to build stronger business ties between the regions.
IDBS is a leading international software company serving the R&D and Healthcare sectors. IDBS’ software is used by more than 40,000 pharmaceutical, clinical and industrial R&D researchers around the world to capture, analyze and secure their valuable data, driving process improvements of more than 30%.
IDBS has selected Burlington, Mass., as the U.S. headquarters of its Healthcare unit business and has recently employed an additional 22 full time employees throughout the East Coast, including 8 in Massachusetts, to service this growing market with the potential of adding additional healthcare posts in Burlington later this year. This move leverages strong existing relationships with the Dana-Farber Cancer Institute and many other life sciences and technology organizations, and demonstrates the growth opportunity for IDBS’s solutions in Massachusetts and beyond.
IDBS’ Founder and CEO Neil Kipling said, “Massachusetts is a natural U.S. hub for our rapidly expanding Translational Medicine business. The local intensity of Advanced Clinical Research, life sciences R&D and industrial-academic collaboration provides an ideal environment to expand our R&D business and to create our U.S. Center-of-Excellence for Healthcare.”
“Massachusetts is a great place for international life sciences companies, such as IDBS, to do business,” said Governor Patrick. “We had a terrific conversation at BIO this past month, and we welcome the company’s decision to headquarters their U.S. healthcare operations here in Massachusetts. Their expansion here will create jobs and further strengthen our innovation economy.”
IDBS is a pioneer in informatics for stratified medicine, bringing together real-world clinical, genetic and research information to drive personalized therapies and improved patient outcomes. IDBS systems are used in advanced clinical research environments in the U.S. and U.K., where the company has recently been selected to provide a national informatics platform for cancer research. This platform has now been productized for pharmaceutical companies, academics and medical centers. [Editor’s note: please see press release titled, “IDBS Leads Stratified Medicine Consortium to Build UK-Wide Cancer Research and Collaboration Platform,” dated June 9, 2011]
The British Consulate in Boston also welcomed the news, “IDBS has long been recognized in the UK as a technology and business leader, winning the 2011 Queen’s Award for International Trade and a £3 million collaborative R&D grant to advance stratified medicine in the UK. We are delighted to see IDBS continue to grow in Massachusetts. This is a fantastic example of business collaboration and fellowship between the UK and Massachusetts, building on the best that both have to offer,” said Dr. Hilary Glidden, Vice Consul and US Lead for Biotechnology & Pharmaceuticals with UK Trade & Investment.
“Massachusetts is a center for innovation in science and technology, and IDBS’s expansion here attests to the strength of our life sciences workforce and the opportunities to partner with leading companies and academic institutions,” said Dr. Susan Windham-Bannister, President and CEO of the Massachusetts Life Sciences Center. “It also speaks to the importance of not resting on our laurels. We need to continue to reach out to outstanding life sciences companies around the world and invite them to Massachusetts. They strengthen our life sciences cluster with their presence.”
“Massachusetts is home to the most innovative companies across the entire life sciences spectrum, working hand-in-hand to move life-changing treatments from the bench to the bedside,” said Robert K. Coughlin, President & CEO of MassBio, a 600+ member life sciences trade association. “We are thrilled to see companies like IDBS grow here, where they play a very important role in our world-class life sciences ecosystem.”
Working from basic research into regulated and multinational collaborative environments, IDBS provides single enterprise platforms that allow companies to make more informed decisions, share innovations and reduce product lifecycles. Customers include Genentech, Amgen, Novartis, Pfizer, GSK, Astra Zeneca, Abbott Laboratories, Dana-Farber Cancer Institute, National Health Service (UK), BASF, Total, L’Oreal, and Syngenta.
IDBS also provides powerful data platforms for scientific collaboration, enabling discreet and pre-competitive co-working between academics and linking academics to industry. These high-context collaboration hubs build trust between scientists, allow real-time sharing of personalized data and secure the intellectual property generated by distributed research activities.
“As a strong supporter of the Life Sciences industry, I am very pleased to see this tangible example of the success of the Life Sciences Initiative through both the important and life changing projects that IDBS works on, and in their expansion of local jobs,” said State Representative Charles Murphy (D-Burlington). “We are thrilled to host their US Healthcare headquarters here in Burlington.”
About IDBS
IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award- winning enterprise technologies and domain knowledge in R&D.
IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, high-tech materials and consumer products, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and products.
Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 2010 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.
